See more : Fattal Holdings (1998) Ltd (FTAL.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Bangkok Genomics Innovation Public Company Limited (BKGI.BK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bangkok Genomics Innovation Public Company Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Federal National Mortgage Association (FNMAT) Income Statement Analysis – Financial Results
- Helens International Holdings Company Limited (9869.HK) Income Statement Analysis – Financial Results
- Okeanis Eco Tankers Corp. (ECO) Income Statement Analysis – Financial Results
- Bambuser AB (publ) (BUSER.ST) Income Statement Analysis – Financial Results
- Thyrocare Technologies Limited (THYROCARE.BO) Income Statement Analysis – Financial Results
Bangkok Genomics Innovation Public Company Limited (BKGI.BK)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
About Bangkok Genomics Innovation Public Company Limited
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Scientific testing services which generates key revenue, and Sale of goods.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 245.39M | 304.77M | 379.31M | 133.80M | 119.01M | 70.74M |
| Cost of Revenue | 129.29M | 150.88M | 214.28M | 98.34M | 84.67M | 66.27M |
| Gross Profit | 116.10M | 153.89M | 165.03M | 35.46M | 34.33M | 4.48M |
| Gross Profit Ratio | 47.31% | 50.49% | 43.51% | 26.50% | 28.85% | 6.33% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 56.97M | 63.86M | 31.95M | 17.82M | 0.00 | 0.00 |
| Selling & Marketing | 28.25M | 30.12M | 27.30M | 7.26M | 0.00 | 0.00 |
| SG&A | 85.22M | 89.45M | 59.12M | 21.66M | 21.64M | 18.33M |
| Other Expenses | -1.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 83.27M | 89.45M | 59.12M | 21.66M | 21.64M | 18.33M |
| Cost & Expenses | 212.55M | 240.33M | 273.40M | 119.99M | 106.31M | 84.60M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.64M | 1.07M | 714.93K | 865.11K | 0.00 | 0.00 |
| Depreciation & Amortization | 15.96M | 14.54M | 8.48M | 7.59M | 0.00 | 1.00 |
| EBITDA | 49.55M | 94.27M | 115.13M | 21.74M | 15.51M | -13.75M |
| EBITDA Ratio | 20.19% | 25.91% | 30.16% | 15.99% | 10.67% | -19.58% |
| Operating Income | 32.84M | 64.44M | 105.91M | 13.80M | 12.69M | -13.85M |
| Operating Income Ratio | 13.38% | 21.14% | 27.92% | 10.32% | 10.67% | -19.58% |
| Total Other Income/Expenses | -894.20K | -178.87K | 22.73K | -512.05K | 2.82M | 99.17K |
| Income Before Tax | 31.94M | 78.66M | 105.93M | 13.29M | 15.51M | -13.75M |
| Income Before Tax Ratio | 13.02% | 25.81% | 27.93% | 9.93% | 13.04% | -19.44% |
| Income Tax Expense | -197.92K | 3.54M | 266.59K | -510.36K | 0.00 | -1.00 |
| Net Income | 32.14M | 75.11M | 105.66M | 13.80M | 15.51M | -13.75M |
| Net Income Ratio | 13.10% | 24.65% | 27.86% | 10.32% | 13.04% | -19.44% |
| EPS | 0.05 | 0.13 | 0.66 | 0.09 | 0.10 | -0.09 |
| EPS Diluted | 0.05 | 0.13 | 0.66 | 0.09 | 0.10 | -0.09 |
| Weighted Avg Shares Out | 600.00M | 600.00M | 160.00M | 160.00M | 160.00M | 160.00M |
| Weighted Avg Shares Out (Dil) | 600.00M | 600.00M | 160.00M | 160.00M | 160.00M | 160.00M |
Source: https://incomestatements.info
Category: Stock Reports